September 25, 2025

AstraZeneca Appeals to Supreme Court in Final Attempt to Challenge Medicare Drug Price Negotiation Program

2 weeks ago talkbio0Tagged AstraZeneca, drug price, Farxiga, Inflation Reduction Act, Medicare, Myasthenic Syndromes, Congenital, Negotiation Program, Supreme Court

AstraZeneca; Medicare Drug Price Negotiation Program; Supreme Court; Inflation Reduction Act; Third Circuit; due process; pharmaceuticals; CMS; drug pricing; Farxiga

Eli Lilly Withdraws $1.9B Phase 2b Obesity Trial Before Launching Enrollment

2 weeks ago talkbio0Tagged bimagrumab, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Eli, Eli Lilly, Obesity, regulatory strategy, tirzepatide, Trial Termination, Zepbound

Eli Lilly; obesity drug; tirzepatide; bimagrumab; trial termination; phase 2b; Zepbound; type 2 diabetes; clinical trial; regulatory strategy

Trump Administration Launches Tariff Probe into Medtech and Pharmaceutical Industries

2 weeks ago talkbio0Tagged Evaluation, Manufacturing, Medical Devices, medtech industry, National Security, pharmaceutical imports, Sectioning technique, semiconductor tariffs, supply chain, tariffs, Transplant Registry Unified Management Program

Trump administration; tariffs; medtech industry; pharmaceutical imports; Section 232 investigation; semiconductor tariffs; national security; supply chain; manufacturing; medical devices

Pfizer’s $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

2 weeks ago talkbio0Tagged biotech acquisition, Glucagon-Like Peptide 1, late-stage clinical development, M&A, Metsera, Obesity, Pfizer, Pharma, pharmaceutical market, Weight Loss

Pfizer; Metsera; obesity drugs; weight loss; pharma M&A; GLP-1; biotech acquisition; pharmaceutical market; late-stage clinical development

Catalent Opens New Global HQ; Fujifilm Launches North Carolina Factory

2 weeks ago talkbio0Tagged Biopharma, Catalent, Cell Culture Techniques, Fujifilm Biotechnologies, global headquarters, Holly Springs, Johnson and Johnson, Manufacturing Facilities, North Carolina, Tampa Florida

Catalent; Global Headquarters; Tampa Florida; Fujifilm Biotechnologies; North Carolina; Holly Springs; manufacturing facility; Johnson & Johnson; cell culture; biopharma

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

2 weeks ago talkbio0Tagged alpha 1-antitrypsin, Artificial Intelligence, Automation, Contraceptives, Oral, eli lilly, Obesity, orforglipron, pharmaceutical manufacturing, Supply Chain Resilience, Surgical construction, Texas Facility

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates

2 weeks ago talkbio0Tagged Acquisitions, BATNA, biotech dealmaking, Licensing, mergers, patent cliffs, pharmaceutical negotiations, pipeline gaps, regulatory uncertainty, reputation, valuation, venture capital

biotech dealmaking; mergers and acquisitions; licensing; venture capital; BATNA; pharmaceutical negotiations; reputation; pipeline gaps; patent cliffs; valuation; regulatory uncertainty

Rising Pharmaceuticals Lowers Headcount After Closing Decatur Factories

2 weeks ago talkbio0Tagged Decatur Illinois, factory closure, layoffs, Pharma Industry, Rising

Rising Pharmaceuticals; factory closure; Decatur Illinois; layoffs; pharma industry; WARN notice; 2025

Glenmark Pharma Signs $1.1 Billion Deal with Hengrui for HER2-Targeted Antibody-Drug Conjugate

2 weeks ago talkbio0Tagged Cancer Therapeutic Procedure, Glenmark, Hengrui Pharma, HER2-targeting antibody drug conjugate, License, milestone payments, Neoplasms, royalties, Trastuzumab Rezetecan

Glenmark; Hengrui Pharma; Trastuzumab Rezetecan; HER2-targeting antibody drug conjugate; oncology; exclusive license; $1.1 billion deal; cancer therapy; milestone payments; royalties

Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure

2 weeks ago talkbio0Tagged Acadia, ACP-101, carbetocin, Clinical trial failure, Hyperphagia, Prader-Willi Syndrome, Soleno, Vykat XR

Acadia Pharmaceuticals; Prader-Willi syndrome; carbetocin; ACP-101; phase 3 trial; hyperphagia; clinical trial failure; Soleno Therapeutics; Vykat XR